Congruent Ventures is raising a second fund two years after a first $92m vehicle closed with an anchor investment from University of California.

Covid-19 Therapeutics Accelerator has launched with $125m to find treatments for the pandemic, $25m of which came from Mastercard.

Alphabet-backed meat substitute provider Impossible said it plans to use the series F funding to shore up against expected disruption by the coronavirus pandemic.

The LinkedIn-backed data streaming platform developer is in talks with investors for a $200m to $300m round that could double its valuation to $5bn.

Mitsubishi Corporation and Dell Technologies Capital helped AI software provider Noodle.ai boost its total funding to $72m.

UnityPoint’s corporate VC unit backed the series C round for Vida Diagnostics, a lung disease imaging technology provider.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The immunotherapy developer, which counts Pfizer, Sanofi, Merck & Co, Eli Lilly, Amgen and Vertex Pharmaceuticals as early investors, has picked up $102m.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.